|
|
Volumn 53, Issue 5, 2010, Pages 614-618
|
|
Efficacy, safety, and tolerability of etravirine with and without darunavir/ritonavir or raltegravir in treatment-experienced patients: Analysis of the etravirine early access program in the United States
a
|
|
Author keywords
Early access program; Etravirine; Nonnucleoside reverse transcriptase inhibitor
|
|
Indexed keywords
ALANINE AMINOTRANSFERASE;
ASPARTATE AMINOTRANSFERASE;
ATAZANAVIR;
CD4 ANTIGEN;
DARUNAVIR;
DARUNAVIR PLUS RITONAVIR;
EMTRICITABINE;
ENFUVIRTIDE;
ETRAVIRINE;
LOPINAVIR;
MARAVIROC;
RALTEGRAVIR;
TENOFOVIR;
ADULT;
ALANINE AMINOTRANSFERASE BLOOD LEVEL;
ARTICLE;
ASPARTATE AMINOTRANSFERASE BLOOD LEVEL;
CD4 LYMPHOCYTE COUNT;
CLINICAL TRIAL;
DEATH;
DIARRHEA;
DRUG EFFICACY;
DRUG SAFETY;
DRUG TOLERABILITY;
DRUG WITHDRAWAL;
FEMALE;
HEALTH CARE ACCESS;
HUMAN;
HUMAN IMMUNODEFICIENCY VIRUS 1;
HUMAN IMMUNODEFICIENCY VIRUS 1 INFECTION;
HUMAN IMMUNODEFICIENCY VIRUS INFECTED PATIENT;
MAJOR CLINICAL STUDY;
MALE;
NAUSEA;
PANCYTOPENIA;
PHASE 3 CLINICAL TRIAL;
PRIORITY JOURNAL;
RASH;
SEPSIS;
SIDE EFFECT;
STEVENS JOHNSON SYNDROME;
TREATMENT RESPONSE;
UNITED STATES;
VIRUS LOAD;
VOMITING;
ADULT;
ANTI-HIV AGENTS;
CD4 LYMPHOCYTE COUNT;
FEMALE;
HIV INFECTIONS;
HIV-1;
HUMANS;
MALE;
MIDDLE AGED;
PYRIDAZINES;
PYRROLIDINONES;
RITONAVIR;
SULFONAMIDES;
UNITED STATES;
VIRAL LOAD;
|
|
EID: 77950259403
PISSN: 15254135
EISSN: None
Source Type: Journal
DOI: 10.1097/QAI.0b013e3181cdebb1 Document Type: Article |
|
Times cited : (24)
|
|
References (8)
|
